Skip to results

Area of interest

Area of interest

Type (1 selected)

Type

Guidance programme (1 selected)

Guidance programme

Showing 21 to 30 of 302

Guidance and quality standards awaiting development
TitleType
Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene for babies 6 months and over to children under 2 years TS ID 11774Technology appraisal guidance
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for early triple negative breast cancer ID 6200Technology appraisal guidance
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID3894]Technology appraisal guidance
Atezolizumab for adjuvant treatment of high-risk locally advanced squamous cell head and neck cancer [ID4052]Technology appraisal guidance
Atezolizumab for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable TS ID 11785Technology appraisal guidance
Atezolizumab with cabozantinib for treating hormone-relapsed metastatic prostate cancer after 1 therapy [ID6203]Technology appraisal guidance
Atezolizumab with chemotherapy for treating relapsing recurrent advanced triple-negative early breast cancer [ID6152]Technology appraisal guidance
Avacincaptad pegol for treating late dry age-related macular degeneration ID6401Technology appraisal guidance
Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793]Technology appraisal guidance
Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794]Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All